CALT vs. STOK, GHRS, OLMA, PHAT, ZYME, PHAR, IGMS, LYEL, ORIC, and AVBP
Should you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include Stoke Therapeutics (STOK), GH Research (GHRS), Olema Pharmaceuticals (OLMA), Phathom Pharmaceuticals (PHAT), Zymeworks (ZYME), Pharming Group (PHAR), IGM Biosciences (IGMS), Lyell Immunopharma (LYEL), ORIC Pharmaceuticals (ORIC), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical preparations" industry.
Stoke Therapeutics (NASDAQ:STOK) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.
Stoke Therapeutics has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -38.72%. Calliditas Therapeutics AB (publ)'s return on equity of -65.47% beat Stoke Therapeutics' return on equity.
In the previous week, Stoke Therapeutics had 17 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 25 mentions for Stoke Therapeutics and 8 mentions for Calliditas Therapeutics AB (publ). Stoke Therapeutics' average media sentiment score of 0.72 beat Calliditas Therapeutics AB (publ)'s score of 0.20 indicating that Calliditas Therapeutics AB (publ) is being referred to more favorably in the news media.
Stoke Therapeutics presently has a consensus price target of $20.57, indicating a potential upside of 43.66%. Calliditas Therapeutics AB (publ) has a consensus price target of $34.00, indicating a potential upside of 53.57%. Given Stoke Therapeutics' higher probable upside, analysts plainly believe Calliditas Therapeutics AB (publ) is more favorable than Stoke Therapeutics.
Stoke Therapeutics received 74 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 72.99% of users gave Stoke Therapeutics an outperform vote while only 60.47% of users gave Calliditas Therapeutics AB (publ) an outperform vote.
Calliditas Therapeutics AB (publ) has higher revenue and earnings than Stoke Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.
2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 11.3% of Stoke Therapeutics shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Stoke Therapeutics has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500.
Summary
Stoke Therapeutics beats Calliditas Therapeutics AB (publ) on 10 of the 18 factors compared between the two stocks.
Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically
Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Calliditas Therapeutics AB (publ) Competitors List
Related Companies and Tools
